| Enzymatic properties of two mutants of reverse transcriptase of human immunodeficiency virus type 1 (tyrosine 181-->isoleucine and tyrosine 188-->leucine), resistant to nonnucleoside inhibitors. |
Loya S, Bakhanashvili M, Tal R, Hughes SH, Boyer PL, Hizi A |
1994 |
| HIV-1 reverse transcriptase: structure predictions for the polymerase domain. |
Barber AM, Hizi A, Maizel JV, Hughes SH |
1990 |
| Genotypic and phenotypic analysis of a novel 15-base insertion occurring between codons 69 and 70 of HIV type 1 reverse transcriptase. |
Lobato RL, Kim EY, Kagan RM, Merigan TC |
2002 |
| Presence of 2',5'-Bis-O-(tert-butyldimethylsilyl)-3'-spiro-5"-(4"-amino-1",2"-oxath iole-2",2"-dioxide) (TSAO)-resistant virus strains in TSAO-inexperienced HIV patients. |
Van Laethem K, Schmit JC, Pelemans H, Balzarini J, Witvrouw M, Pérez-Pérez MJ, Camarasa MJ, Esnouf RM, Aquaro S, Cenci A, Perno CF, Hermans P, Sprecher S, Ruiz L, Clotet B, Van Wijngaerden E, Van Ranst M, Desmyter J, De Clercq E, Vandamme AM |
2000 |
| Tetrahydronaphthalene lignan compounds as potent anti-HIV type 1 agents. |
Hara H, Fujihashi T, Sakata T, Kaji A, Kaji H |
1997 |
| Characterization of HIV-1 strains isolated from patients treated with TIBO R82913. |
Vandamme AM, Debyser Z, Pauwels R, De Vreese K, Goubau P, Youle M, Gazzard B, Stoffels PA, Cauwenbergh GF, Anne J |
1994 |
| Lethal mutagenesis of HIV by mutagenic ribonucleoside analogs. |
Loeb LA, Mullins JI |
2000 |
| Sequence Quality Analysis Tool (SQUAT) for HIV-1 Protease and Reverse Transcriptase. |
Delong AK, Wu M, Bennett D, Parkin N, Wu Z, Hogan JW, Kantor R |
2011 |
| Transmitted antiretroviral drug resistance and thumb subdomain polymorphisms among newly HIV-1 diagnosed patients infected with CRF01_AE and CRF07_BC virus in Guangdong Province, China. |
Yang C, Liu S, Zhang T, Hou Y, Liu X, Gao Y, Yang G, Wang Z, Chen H, Li M, Zhu Z |
2012 |
| Drug resistance profiles of recombinant reverse transcriptases from human immunodeficiency virus type 1 subtypes A/E, B, and C. |
Quan Y, Brenner BG, Marlink RG, Essex M, Kurimura T, Wainberg MA |
2003 |
| Neutralizing antibodies directed against the V3 loop select for different escape variants in a virus with mutated reverse transcriptase (M184V) than in wild-type human immunodeficiency virus type 1. |
Inouye P, Cherry E, Hsu M, Zolla-Pazner S, Wainberg MA |
1998 |
| Combination of a drug targeting the cell with a drug targeting the virus controls human immunodeficiency virus type 1 resistance. |
Lori F, Malykh AG, Foli A, Maserati R, De Antoni A, Minoli L, Padrini D, Degli Antoni A, Barchi E, Jessen H, Wainberg MA, Gallo RC, Lisziewicz J |
1997 |
| Activity of reverse transcriptase inhibitors in monocyte-derived dendritic cells: a possible in vitro model for postexposure prophylaxis of sexual HIV transmission. |
Van Herrewege Y, Penne L, Vereecken C, Fransen K, van der Groen G, Kestens L, Balzarini J, Vanham G |
2002 |
| Rapid alternation of drug therapy is highly efficient in suppressing the emergence of mutant drug-resistant HIV strains in cell culture. |
Balzarini J, De Clercq E |
2001 |
| Selective inhibition of HIV replication by adriamycin in macrophages but not in lymphocytes. |
Bergamini A, Perno CF, Balzarini J, Capozzi M, Marinelli L, Milanese G, Pesce CD, Calió R, Rocchi G |
1992 |
| HIV inhibitors targeted at the reverse transcriptase. |
De Clercq E |
1992 |
| Near full-length genomic analysis of a novel subtype A1/C recombinant HIV type 1 isolate from Canada. |
Ntemgwa ML, Toni TD, Brenner BG, Routy JP, Moisi DD, Oliveira M, Wainberg MA |
2008 |
| Insulin-like growth factor 1 and insulin inhibit HIV type 1 replication in cultured cells. |
Germinario RJ, DeSantis T, Wainberg MA |
1995 |
| Genotypic analysis of the protease and reverse transcriptase of HIV type 1 isolates from recently infected injecting drug users in western China. |
Liao L, Xing H, Li X, Ruan Y, Zhang Y, Qin G, Shao Y |
2007 |
| Long-term exposure of HIV type 1-infected cell cultures to combinations of the novel quinoxaline GW420867X with lamivudine, abacavir, and a variety of nonnucleoside reverse transcriptase inhibitors. |
Balzarini J, De Clercq E, Carbonez A, Burt V, Kleim JP |
2000 |
| Development of a cell-based enzyme-linked immunosorbent assay for high-throughput screening of HIV type 1 entry inhibitors targeting the coreceptor CXCR4. |
Zhao Q, Lu H, Schols D, De Clercq E, Jiang S |
2003 |
| Lamivudine resistance of HIV type 1 does not delay development of resistance to nonnucleoside HIV type 1-specific reverse transcriptase inhibitors as compared with wild-type HIV type 1. |
Jonckheere H, Witvrouw M, De Clercq E, Anné J |
1998 |